Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock by Calandra, Thierry et al.
982
Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l,
Interferon-a, and Interferon-v in the Serum of Patients with Septic Shock
Thierry Calandra, Jean-Daniel Baumgartner,
Georges E. Grau, Mei-Miau Wu,
Paul-Henri Lambert, Joop Schellekens, Jan Verhoef,
Michel P. Glauser, and the Swiss-Dutch
J5 Immunoglobulin Study Group*
From the Division of Infectious Diseases, Department of Internal
Medicine, Centre Hospitalier Universitaire J4ludois, Lausanne, and
Department of Pathology, World Health Organization Immunology
Research and Training Centre, University of Geneva, Switzerland, and
Clinical Bacteriology, State University of Utrecht, The Netherlands
Serum concentrations of immunoreactive tumor necrosis factor/cachectin (TNF), interleukin-
1jJ (IL-1jJ), interferon-y (IFN"(), and interferon-a (IFNa) were prospectively measured in 70
patients with septic shock to determine their evolution and prognostic values. In a univariate
analysis, levels of TNF (P = .002) and IL-1jJ (P = .05) were associated with the patient's out-
come, but not IFNa (P = .15) and IFN"( (P = .26). In contrast, in a stepwise logistic regression
analysis, the severity of the underlying disease (P = .01), the age of the patient (P = .02), the
documentation of infection (nonbacteremic infections vs. bacteremias, P = .03), the urine output
(P = .04), and the arterial pH (P = .05) contributed more significantly to prediction of patient
outcome than the serum levels of TNF (P = .07). After 10 days, the median concentration of
TNF was undetectable «100 pg/ml) in the survivors, whereas it remained elevated (305 pg/ml,
P = .002) in the nonsurvivors. Thus, in patients with septic shock due to various gram-negative
bacteria, other parameters than the absolute serum concentration of immunoreactive TNF con-
tributed significantly to the prediction of outcome.
Tumor necrosis factor/cachectin (TNF) is a cytokine pro-
duced by activated macrophages [1] shown in experimental
studies to be a primary mediator of the deleterious effects of
endotoxin [2-10]. Recently, in patients with meningococce-
mia, high serum levels of TNF, interleukin-6, interleukin-l,
and interferon-y and low serum levels of fibrinogen were
shown to correlate with the severity of the disease [11-13].
So far, the kinetics of TNF serum levels in humans has been
determined in healthy volunteers challenged with a single in-
travenous injection of endotoxin [8]. However, similar data
on the evolution of serum levels of TNF have not been ob-
tained in patients with gram-negative bacteremia or with septic
shock.
Therefore, we prospectively measured the serum concen-
trations of immunoreactive TNF in patients with septic shock
due mainly to gram-negative organisms, to determine the evo-
lution of the serum levels of TNF during the course of septic
shock and to relate these levels to patient outcome. Serum
concentrations of immunoreactive interleukin-lji (IL-I/3),
Received 25 July 1989; revised 14 November 1989.
Presented in part at the 28th Interscience Conference on Antimicrobial
Agents and Chemotherapy (abstract 1340), Los Angeles. October 1988.
Grant support: 3.825-0.86, Fonds National Suisse de la Recherche Sci-
entifique.
Reprints and correspondence: Dr. Thierry Calandra, Division of Infec-
tious Diseases. Dept. ofInternal Medicine, Centre Hospitalier Universitaire
Vaudois, CH-lOlI Lausanne, Switzerland.
* See Acknowledgment.
The JDuma! of Infectious Diseases 1990;161:982-987
© 1990 by The University of Chicago. All rights reserved.
0022-1899/90/6105-0026$01.00
interferon-a (IFNa), and interferon-y (IFN')') were also mea-
sured to study the interplay of these cytokines and TNF in
patients with septic shock.
Materials and Methods
The patients enrolled were part of a prospective, double-blind trial
that investigated the efficacy of two IgG preparations for the treat-
ment of gram-negative septic shock. The results of that trial includ-
ing the detailed information about the study design, the tested IgG
preparations, the case review,and data analysis have been reported
elsewhere [14]. The type of IgG allocated at randomization had no
significant impact on the outcome of patients (P = .30) and on the
serum concentrations of cytokines (study entry: P = .72 for TNF,
P = .73 for IL-ljJ, P = .55 for IFNa, P = .75 for IPN"(; day 1:
P = .10 for TNP, P = .74 for IL-ljJ, P = .65 for IPNa, P = .74
for IFN"(; day 10: P = .25 for TNP, P = .09 for IL-ljJ, P = .37
for IPNa. P = .06 for IFN"(). Therefore, the two treatment groups
were pooled for the purpose of the present study.
Patienteligibility. Patients eligible for study were those in sep-
tic shock definedby the followingtwocriteria: The first was the pres-
ence of shock, defined by a systolic blood pressure <90 mm Hg or
a decrease of>30 mm Hg in a hypertensive patient, in the absence
of other causes of shock such as hypovolemia, myocardial infarc-
tion, or pulmonary embolism. In addition, at least one of the fol-
lowing signs had to be present: oliguria «30 ml/h), hypothermia
«36°C), hypoxemia (oxygen tension <70 mm Hg), metabolic aci-
dosis (pH <7.3 or base excess <-10 mmolll), coagulation abnor-
malities(prothrombin time <50% or partial thromboplastintime >40
s or elevation of fibrin split products), or thrombocytopenia «100
X lQ9/1 or a decrease of >50% of a previously abnormal value).
The second criterion was the presence of an infection, that is, a bac-
teremia or a microbiologically documented focal infection. The iso-
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latedorganism wasconsidered to be thepathogen ofsepsisif recovered
withina 24-h period beforeor after the onset of shock. Postmortem
positive blood cultures were disregarded. In a few patients all cul-
tures remained sterile, possibly because of the concomitant use of
broad-spectrumantibiotics. However, despite sterile cultures these
patients were included in the study because their clinical courses
were highly suggestive of an ongoing infection.
Serum sampling and cytokines radioimmunoassays. Serum was
collected in sterile tubes at study entry (i .e., before the infusion of
immunoglobulins) and at days I and 10(in those surviving). Serum
sampleswere aliquoted, coded with numbers, and stored at -70°C
until assayed blindly. Serum samples underwent at the most two
freeze-thaw cyclesbeforebeing assayed.Serum TNF, IL-lt), IFNa,
and IFN-y wereassayedwitha competitiveinhibitionradioimmuno-
assay (IRE-Medgenix, Fleurus, Belgium) [12].The limits of detec-
tion of these radioimmunoassays were 100pg/mlof TNF, 150pg/ml
for IL-It), I unit/ml ofIFNa, and 1 unit/ml ofIFN-y. When mea-
sured in healthycontrols, the serum levelsof these cytokines were
below the respective limit of detection.
Definitions. The severityof the underlyingdisease was reported
according to theclassification proposed byMcCabeandJackson[15].
Death wasattributed to septic shock if the patientdied of irreversi-
ble shock, of a direct consequence of shock (i.e., multiple organ
failure), or of a complicationof infection(i.e., diffusehemorrhage
related to disseminated intravascularcoagulation). Other causes of
death were attributed to the underlying diseases.
Statistical analyses. Statistical analysesof clinical and labora-
tory data were done using the X2 test or Fisher's exact test for the
comparisons of proportions and the Kruskall-Wallis test for com-
paring intergroupdifferences. Wilcoxon signed-rank test was used
to test the interday difference of the serum levelsof cytokines. All
reportedsignificance levels are two-sided. A stepwise logisticregres-
sion was performed to select the most predictive variables of the
patient'soutcome and to assess their relative importance in this re-
spect. For this particular analysisusingthe BMDPLRprogram, the
maximumlikelihoodratio method and all other default valueswere
used for selecting the prognostic factors [16].
Results
Of the 100 patients with septic shock randomized in the
study of treatment of gram-negative septic shock with two IgG
preparations, 78 patients had sera collected for the measure-
ment of TNF, IL-II3, IFNa, and IFNI'. Eight patients were
excluded from this study because shock either was not due
to sepsis (5) or was not present at study entry (3). Thus, we
report here on the prognostic values and on the evolution of
the serum levels of these four cytokines in 70 patients with
septic shock.
Etiology of septic shock. The pathogens of septic shock
were gram-negative bacteria in 54 patients (77 %) - pure cul-
ture in 36 patients and mixed culture in 18. Gram-positive
bacteria were isolated in 5 patients (7%) and yeasts in 3 (4%).
In 8 patients (11 %) all cultures remained sterile. Of the 70
patients, 41 (59 %) were bacteremic, of whom 37 (90 %) were
infected by gram-negative bacteria (pure gram-negative bac-
teremia, 30 patients; mixed gram-negative bacteremia, 7), 3
(7 %) by gram-positive bacteria, and I (3 %) by a yeast.
Characteristics of the patients at study entry. Of the 70
patients with septic shock, 37 (53%) survived and 33 (47%)
died. The survivors and the nonsurvivors were similar with
respect to the following parameters (table I): age, duration
of shock before study entry, body temperature, mean arterial
pressure, leukocyte count with differential, thrombocyte count,
and alveolar-arterial oxygen difference. In contrast, the two
groups of patients differed in gender ratio, severity of the un-
derlying disease, documentation of infection, urine output,
and pH. With respect to therapy, a similar proportion of the
survivors and of the nonsurvivors were treated with vasopres-
sors, with high-dose corticosteroids, and with appropriate an-
timicrobial treatment.
Tumor necrosis factor. Immunoreactive TNF was detected
in 55 (79 %) of 70 patients (figure I). The median serum lev-
els of TNF at study entry (i.e., before the infusion of immu-
noglobulins) were higher in the nonsurvivors (330 pg/ml;
range, <100-3500) than in the survivors (180 pglml; range,
<100-1300; P = .002). Thus, in patients with septic shock
due to various microorganisms, the concentrations of im-
munoreactive TNF was associated with outcome. The serum
levels of TNF did not correlate with duration of shock before
study entry (r = - .07,P = .59), or with duration of survival
in those patients ultimately dying of shock (r = .04, P =
.83). Since there was an overlap of the serum levels ofTNF
measured in the survivors and in the nonsurvivors, we deter-
mined the concentration ofTNF that would best discriminate
these two groups of patients. The best cutoff value of serum
TNF was at 250 pg/ml. Indeed, of 42 patients with TNF lev-
els <250 pg/ml, 31 (74%) survived compared with only 6
(21%) of 28 patients with TNF levels >250 pg/ml (P =
.00005). For predicting survival, this cutoff value of 250 pg/ml
had a sensitivity of 84% (31137), a specificity of 67 % (22/33),
a positive predictive value of 74% (31142), and a negative
predictive value of 79% (22/28).
In the 54 patients with gram-negative infections, the same
correlation was observed between the serum levels of TNF
and the outcome of the patients (P = .02). Six of the 8 pa-
tients infected with gram-positive organisms or with yeasts
had elevated concentrations of TNF (140, 170, 180, 200, 200,
and 530 pg/ml) at study entry.
To determine the evolution of the serum levels ofTNF dur-
ing the course of septic shock, TNF was measured at days
I and 10 after study entry. The median concentration of TNF
in the survivors decreased from 180 pg/ml at study entry, to
150 pg/ml (range, <100-600) at day I, and to <100 pglml
(range, <100-400) at day 10 (P = .57 and P = .008, respec-
tively, when compared with levels ofTNF at study entry; figure
2A). In contrast, the median concentration ofTNF remained
high in the nonsurvivors; it was 330 pg/ml at study entry, 250
pg/ml (range, <100-1500) at day I, and 305 pg/ml (range,
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Table 1. Characteristics of survivors and of nonsurvivors at study entry.
Characteristics Survivors Nonsurvivors P
No. of patients 37 33
Age, y 52 (7-78) 60 (21-76) .10
Gender, no. M/no. F 19/18 25/8 .06
Severity of underlying disease, no. (%)
Rapidly fatal 0 6 (18) ]
Ultimately fatal 9 (24) 9 (27) .02
Nonfatal 28 (76) 18 (55)
Documentation of infection, no. (%)
Bacteremias 22 (59) 19 (58) ]
Nonbacteremic infections 8 (22) 13 (39) .06
No organism isolated 7 (19) I (3)
Duration of shock, h 10 (2-36) 12 (2-144) .55
Body temperature, °C 38.2 (35.0-40.4) 38.0 (34-40.4) .39
Mean arterial pressure, mm Hg 62 (17-97) 62 (23-85) .96
Diuresis, ml/h 30 (0-190) 0(0-170) .0007
Leukocyte, 109/1 8.2 (0.1-14.0) 6.1 (0.1-100.0) .48
% band forms 20 (0-70) 19 (0-75) .73
Thrombocyte, 109/1 88 (17-370) 86 (12-400) .75
Arterial pH 7.40 (7.27-7.57) 7.34 (7.14-7.52) .007
Alveolar-arterial oxygen difference, mm Hg 170 (15-583) 222 (35-575) .09
Vasopressor therapy, no. (%) 27 (73) 30 (91) .11
Dose, ug/kg/rnin 7 (3-24) 9 (2-32) .68
High-dose steroid therapy, no. (%) 13 (35) 13 (39) .90
Appropriate antimicrobial therapy, no. (%) 36 (97) 32 (97) .72
NOTE. All data are median (range) unless specified otherwise.
Figure 1. Serum levels of immunoreactive TNF measured at study
entry (before infusion of immunoglobulins) in survivors and non-
survivors. Horizontal bars represent median concentrations ofTNF
in each group of patients. Broken line shows limit of detection of
radioimmunoassay «100 pg/ml).
<100-480) at day 10 (P = .78and P = .69, respectively, when
compared with levels of TNF at study entry). As a conse-
quence, at days I and 10 the concentrations ofTNF remained
significantly higher in the nonsurvivors than in the survivors
(P = .01 and P = .002, respectively). Thus, the serum con-
centrations of TNF remained elevated in 11of the 13 nonsur-
vivors that were still alive at day 10. Seven of these II patients
died of irreversible septic shock between 10 and 15 days after
study entry; 5 of the 7 had a persistent gram-negative bacter-
emia, I a cavitating gram-negative pneumonia, and I an acute
respiratory distress syndrome. The other 4 patients died of
septic shock after 27-39 days. Their clinical course wascharac-
terized by a transient improvement in their hemodynamic
profile, followed by a recurrence of septic shock, due to an
unresolved primary infection in 3 patients and to a gram-
negative pulmonary superinfection in a ventilated patient.
IL-I[3, IFNa., and IFN",. The median concentrations ofIL-
1[3 at study entry were significantly higher in the nonsurvivors
(480 pg/ml; range, <150-2920) than in the survivors (300
pg/ml; range, <150-3260; P = .05; figure 2B). In contrast
to TNF, this difference in the concentration oflL-I[3 between
the nonsurvivors and the survivors did not persist at day I
(510 pg/ml [range, <150-5250] vs. 450 pg/rnl [range,
<150-4000], P = .62) and at day 10 (470 pg/ml [range,
<150-1060] vs. 310 pg/ml [range, <150-1460], P = .12). Se-
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Figure 2. Evolution of serum levels of TNF (A), IL-111 (B), and
IFNa (C) in survivors (.&) and nonsurvivors (_) during course of
septic shock. Concentrations of cytokines are given as median with
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rum levels of IL-I{3 did not correlate with the serum levels
of TNF, when considering either the whole group of patients
(r = -.009, P = .94) or those patients with gram-negative
infections (r = -.04, P = .75).
Serum concentrations of IFNa (4.98 units/ml [range,
<1-36.9] in the survivors and 7.14 units/ml [range, <1-16.6]
in the nonsurvivors, P = .15; figure 2C) and of IFNy «1
unit/ml [range, <1-19.2] in the survivors and <1 unit/ml [range,
<1-18.9] in the nonsurvivors, P = 27) did not correlate with
the patient's outcome and remained unchanged during the
course of septic shock. As for IL-1{3, neither the serum levels
ofIFNa (r = -.079, P = .52) nor those ofIFN-y (r = .161,
P = .20) correlated with the serum levels of TNF.
Logistic regression analysis. Since some of the variables
p
.01
.02
C:SE
ratio
-2.52
2.41
0.81
0.03
-2.05
0.06
1.93 0.86 2.24 .03
-1.37 1.55 -0.89 .38
-0.02 0.01 -2.12 .04
-0.09 0.04 -2.03 .05
2.08 1.14 1.82 .07
-0.06 0.03 -1.68 .10
90.63 34.65 2.62
Standard
Coefficient error
(C) (SE)Variables
Table 2. Results of logistic regression analysis.
Severity of underlying disease
Age
Documentation of infection
Nonbacteremic infections
vs, bacteremias
Bacteremias vs, no
organism isolated
Urine output
Arterial pH
TNF
Temperature
Constant
are intercorrelated, their joint effect on patient outcome can-
not be assessed univariately. Therefore, we performed a step-
wise logistic regression analysis to assess the importance of
TNF in the presence of other factors. On the basis of data
from the literature [17, 18] and our exploration of the data
of our 70 patients, the following 13 clinical and laboratory
variables were evaluated: age, gender, severity of underlying
disease, documentation of infection, body temperature, blood
pressure, urine output, serum concentrations (of TNF, IL-
1{3, and IFNa), arterial pH, alveolar-arterial oxygen differ-
ence, and leukocyte count. In a stepwise manner, 7 of the 13
variables considered initially were included in the model, of
which 6 contributed significantly to prediction of patient out-
come (table 2). The most significant of these variables were
the severity of underlying disease (P = .01), age (P = .02),
documentation of infection (nonbacteremic infections vs. bac-
teremias, P = .03, and bacteremias vs. no organism isolated,
P = .38), urine output (P = .04), and arterial pH (P = .05).
In this statistical model, immunoreactive TNF was at only
the limit of significance (P = .07) and the temperature was
not statistically significant (P = .10).
To further assess how good the model was, we examined
the percentage of correct prediction of patient outcome using
either all or only some of the significant variables. With all
6 variables, one could predict the survival of the 70 patients
correctly in up to 84% of the cases. When TNF levels were
not taken into account, the correct prediction was still 83 %,
indicating that TNF contributed marginally to the prediction
of patient outcome when the other 5 clinical and laboratory
parameters were included. When only severity of underlying
disease, documentation of infection, and age were included,
patient outcome was predicted correctly up to 75%. The ac-
curacy of the prediction dropped to 62 % if only severity of
underlying disease was taken into account.
NOTE. The ratio of coefficient to standard error (C:SE) can be read roughly as
t statistics. Absolute value <2 indicates variable of minor effect in presence of other
variables.
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Discussion
In the present study, we examined the evolution and the prog-
nostic value of the serum levels of immunoreactive TNF, IL-
1(1, IFNa, and IFNI' in 70 patients with septic shock due to
various microbial agents, mainly gram-negative bacteria. Im-
munoreactive TNF was detectable in 79 %of our patients with
established septic shock. Recently, de Groote et al. [19] mea-
sured plasma levels of immunoreactive TNF in 38 patients
with presumed sepsis, of whom 14 had gram-negative and
2 had pneumococcal bacteremias. Only 6 (16%) of these 38
patients had detectable TNF levels. In 43 critically ill septic
patients, of whom 11 had gram-positive and 9 had gram-
negative bacteremias, Debets et al. [20] detected plasma lev-
els of immunoreactive TNF in only 11 patients (25 %). Thus,
the data of our present study demonstrate that in contrast to
patients with sepsis, most patients with established septic shock
due to various gram-negative bacteria have imniunoreactive
TNF present in their serum. In addition, the detection of
elevated TNF levels in the serum of 6 of 8 patients with septic
shock due to gram-positive bacteria or yeasts suggests that
TNF might also playa role during the development of these
infections.
In a univariate analysis, the serum levels ofTNF measured
at study entry were significantly associated with patient out-
come. However, there was a wide overlap between the sur-
vivors and the nonsurvivors. Other investigators have also
found that levels of biologically active [11] or immunoreac-
tive [12] TNF were associated with outcome in patients with
meningococcemia, but they did not determine the relative
prognostic value of TNF and of other clinical and laboratory
variables.
In order to determine the relative importance of the vari-
ous prognostic factors of outcome in our patients and to as-
sess whether the serum levels ofTNF would remain significant
once these factors were taken into account, we performed a
stepwise logistic regression analysis. In this analysis, five sim-
ple clinical and laboratory variables were significantly as-
sociated with the outcome of the patients, while serum levels
of immunoreactive TNF were at the limit of the statistical
significance. Indeed, the percentage of correct prediction of
patient outcome was increased only from 83 % to 84 %by add-
ing TNF to these five variables, showing that TNF itself had
a negligible impact for prediction. Thus, our observations sug-
gest that in patients with established septic shock, the abso-
lute serum concentration of immunoreactive TNF is not a
prime indicator of the severity of the patient's condition and
might be of limited value in predicting patient outcome.
Since TNF has been unequivocally shown to be of critical
importance in the development of the clinical and humoral
manifestations of septic shock in animals [2-7, 21] and in hu-
mans [8, 22] challenged with whole gram-negative bacteria
or with lipopolysaccharide, the results of the logistic regres-
sion analysis should be cautiously interpreted with regard to
the role played by TNF in the pathogenesis of septic shock
in our patients. First, measuring serum concentrations of im-
munoreactive TNF does not discriminate biologically active
TNF from potentially inactive TNF once it is bound to recep-
tors, plasma proteins, or inhibitors. Second, in contrast to ro-
dents [3, 7] or primates [6] dying a few hours after an acute
challenge with gram-negative bacteria, endotoxin, or recom-
binant TNF, only 30% of our patients died within 24 h of an
overwhelming and irreversible septic shock. The other 70%
died of direct or indirect consequences of septic shock at a
median of 10 days (range, 2-39) after the onset of septic shock.
In addition, the magnitude and evolution of the serum con-
centrations of TNF in our patients differed strikingly from
those observed in patients with fulminant meningococcal septic
shock, in whom the levels of biologically active [II] or im-
munoreactive TNF [12J were much higher, possibly because
meningococcal septic shock follows a particular fulminant
course in comparison with septic shock caused by other gram-
negative organisms. Moreover, while immunoreactive TNF
levels in volunteers were undetectable 4 h after a single injec-
tion of endotoxin [8], 79 % of our patients had detectable lev-
els of TNF 10 h after the development of shock, probably
reflecting differences of infectious stimuli between volunteers
and patients. Indeed, we observed two different evolutions of
the serum levels of immunoreactive TNF during the course
of septic shock. In patients surviving septic shock, the con-
centrations of TNF had decreased to undetectable levels 10
days after the acute episode, whereas in II of the 13 nonsur-
vivors TNF levels remained elevated.
The persistence of high levels of TNF in the 13 nonsur-
vivors was related to unresolved primary infections, as shown
by the documentation of recurrent gram-negative infections
in 6. This could suggest that in patients with septic shock,
the persistence of high levels of immunoreactive TNF despite
appropriate antimicrobial therapy might be an early clue for
a persistent infection as well as for the development of multi-
ple organ failure. Altogether, the present results might there-
fore indicate that in patients dying from the consequences of
septic shock, the host response to TNF production might be
somewhat different from that observed in animals after an
acute challenge and suggest that once septic shock is estab-
lished, other variables should be considered for predicting
patient outcome.
With regard to levels of other cytokines, we found in a
univariate analysis that the serum levels of IL-l(1 were also
significantly higher in the nonsurvivors than in the survivors
(P = .05). However, the relation between IL-l(1 and patient
outcome did not remain significant when other prognostic vari-
ables were taken into account in the logistic regression anal-
ysis. Since it has been shown that the production ofIL-l(1 can
be induced by TNF both in vitro [23] and in vivo [24], and
since IL-l(1 experimentally potentiates the lethal effect ofTNF
[25], we examined the interplay ofTNF and IL-I(1 in the se-
rum ofour patients. There was no correlation between serum
levels ofTNF and ofIL-l(1, either in the overall patient popu-
lation or in patients with documented gram-negative infec-
tions. These results contrast with those observed by Girardin
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et al. [12] and by Waage et al. [13] in children with purpura
fulminans, possibly because the correlation between TNF and
IL-113 is restricted to meningococcal septic shock.
With regard to IFNa and iFNI' serum levels, neither was
related to patient outcome. A similar lack of correlation be-
tween IFNI' and outcome was observed by Waage et al. [13]
in patients with meningococcal septic shock, in contrast to
the results of Girardin et al. [12] in children with severe menin-
gococcal purpura.
In conclusion, the results of this study showed that im-
munoreactive TNF and, to a lesser extent, IL-113 are produced
in the serum of patients with septic shock due to various gram-
negative bacteria, but also due to gram-positive bacteria and
to yeasts. Different evolutions of the serum level of TNF were
observed in survivors and in nonsurvivors during the course
of septic shock. In the survivors, serum TNF progressively
decreased to undetectable levels, while it remained elevated
for at least IO days in the vast majority of the nonsurvivors
and was often related to the presence of a persistent infection.
However, although associated univariately with patient out-
come, TNF was shown in a multivariate analysis to contrib-
ute less significantly to the prediction of outcome than five
simple clinical and laboratory variables.
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